You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 25, 2024

DELAFLOXACIN MEGLUMINE - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic drug sources for delafloxacin meglumine and what is the scope of freedom to operate?

Delafloxacin meglumine is the generic ingredient in one branded drug marketed by Melinta and is included in two NDAs. There are thirteen patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Delafloxacin meglumine has one hundred and twelve patent family members in twenty-eight countries.

One supplier is listed for this compound.

Summary for DELAFLOXACIN MEGLUMINE
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for DELAFLOXACIN MEGLUMINE
Generic Entry Dates for DELAFLOXACIN MEGLUMINE*:
Constraining patent/regulatory exclusivity:
Dosage:
POWDER;INTRAVENOUS
Generic Entry Dates for DELAFLOXACIN MEGLUMINE*:
Constraining patent/regulatory exclusivity:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for DELAFLOXACIN MEGLUMINE
Anatomical Therapeutic Chemical (ATC) Classes for DELAFLOXACIN MEGLUMINE

US Patents and Regulatory Information for DELAFLOXACIN MEGLUMINE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Melinta BAXDELA delafloxacin meglumine POWDER;INTRAVENOUS 208611-001 Jun 19, 2017 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Melinta BAXDELA delafloxacin meglumine TABLET;ORAL 208610-001 Jun 19, 2017 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Melinta BAXDELA delafloxacin meglumine POWDER;INTRAVENOUS 208611-001 Jun 19, 2017 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Melinta BAXDELA delafloxacin meglumine TABLET;ORAL 208610-001 Jun 19, 2017 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for DELAFLOXACIN MEGLUMINE

Country Patent Number Title Estimated Expiration
Japan 2016166368 アルキル化シクロデキストリン組成物ならびにその調製方法および使用方法 (ALKYLATED CYCLODEXTRIN COMPOSITION AS WELL AS PREPARATION METHOD AND USE METHOD THEREOF) ⤷  Sign Up
Poland 3056492 ⤷  Sign Up
South Korea 20160033795 알킬화된 시클로덱스트린 조성물 및 이의 제조 및 사용 방법 (ALKYLATED CYCLODEXTRIN COMPOSITIONS AND PROCESSES FOR PREPARING AND USING THE SAME) ⤷  Sign Up
Japan 6039721 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for DELAFLOXACIN MEGLUMINE

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
3214083 CA 2021 00002 Denmark ⤷  Sign Up PRODUCT NAME: DELAFLOXACIN ELLER ET SALT ELLER ESTER DERAF, SAERLIGT DELAFLOXACIN MEGLUMIN; REG. NO/DATE: EU/1/19/1393 20191219
3214083 PA2021002 Lithuania ⤷  Sign Up PRODUCT NAME: DELAFLOKSACINAS ARBA JO DRUSKA AR ESTERIS, ISKAITANT DELAFLOKSACINO MEGLUMINA; REGISTRATION NO/DATE: EU/1/19/1393 20191216
3214083 122021000010 Germany ⤷  Sign Up PRODUCT NAME: DELAFLOXACIN ODER EIN SALZ ODER ESTER DAVON, EINSCHLIESSLICH DELAFLOXACINMEGLUMIN.; REGISTRATION NO/DATE: EU/1/19/1393 20191216
3214083 132021000000011 Italy ⤷  Sign Up PRODUCT NAME: DELAFLOXACINA O UN SUO SALE O ESTERE, INCLUSA LA DELAFLOXACINA MEGLUMINA(QUOFENIX); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/19/1393, 20191219
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.